Holen Sie sich die Stockscreener-App
23.57
1.29%
0.30
Vorhandelsmarkt:
24.50
0.93
+3.95%
Schlusskurs vom Vortag:
$23.27
Offen:
$23.53
24-Stunden-Volumen:
185.46K
Relative Volume:
0.52
Marktkapitalisierung:
$291.87M
Einnahmen:
$9.71M
Nettoeinkommen (Verlust:
$-29.96M
KGV:
-6.773
EPS:
-3.48
Netto-Cashflow:
$-14.79M
1W Leistung:
-5.42%
1M Leistung:
-12.02%
6M Leistung:
-17.18%
1J Leistung:
-13.03%
1-Tages-Spanne:
$23.00
$23.97
1-Wochen-Bereich:
$22.29
$26.29
52-Wochen-Spanne:
$18.35
$39.92
Xoma Royalty Corp Stock (XOMA) Company Profile
Firmenname
Xoma Royalty Corp
Sektor
Branche
Telefon
510-204-7239
Adresse
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
23.57 | 288.15M | 9.71M | -29.96M | -14.79M | -3.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-17 | Eingeleitet | The Benchmark Company | Buy |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2021-09-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-06-29 | Eingeleitet | Aegis Capital | Buy |
| 2021-01-19 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-17 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-05 | Hochstufung | Wedbush | Neutral → Outperform |
| 2017-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-11 | Bestätigt | Wedbush | Outperform |
| 2015-07-23 | Herabstufung | Jefferies | Buy → Hold |
| 2015-07-22 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2015-07-22 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-10-10 | Fortgesetzt | ROTH Capital | Buy |
| 2014-04-29 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-03-11 | Herabstufung | MLV & Co | Buy → Hold |
| 2014-03-05 | Bestätigt | Ladenburg Thalmann | Buy |
| 2013-10-31 | Bestätigt | MLV & Co | Buy |
| 2013-05-09 | Bestätigt | Ladenburg Thalmann | Buy |
| 2012-05-14 | Eingeleitet | Cowen & Co | Outperform |
| 2011-03-31 | Bestätigt | MLV Capital | Buy |
| 2011-03-23 | Bestätigt | RBC Capital Mkts | Outperform |
| 2011-01-06 | Bestätigt | Ladenburg Thalmann | Buy |
| 2011-01-04 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Xoma Royalty Corp Aktie (XOMA) Neueste Nachrichten
Xoma stock rating reinstated as Hold by TD Cowen after Generation Bio acquisition - Investing.com South Africa
Buyback Watch: What drives XOMA Royalty Corporations stock priceJuly 2025 Market Mood & Risk Controlled Stock Alerts - baoquankhu1.vn
XOMA Royalty (NASDAQ:XOMA) Upgraded at Zacks Research - Defense World
XOMA Royalty (NASDAQ:XOMA) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
XOMA Royalty’s Preferreds Still Offer Compelling Income Despite Call Risk (NASDAQ:XOMA) - Seeking Alpha
Generation Bio pays landlord $21.5M to escape lease early after Xoma buyout - The Business Journals
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share By Investing.com - Investing.com South Africa
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Generation Bio; GBIO delisted from Nasdaq - Investing.com
XOMA Royalty Completes Generation Bio Acquisition and Merger - TipRanks
XOMA Royalty Corporation Completes Acquisition of Generation Bio Co. Through Tender Offer - Quiver Quantitative
Generation Bio investors cashed out at $4.2913 a share in XOMA takeover - Stock Titan
Published on: 2026-02-09 02:34:15 - baoquankhu1.vn
Gainers Report: What is the next catalyst for XOMA Royalty CorporationShare Buyback & Accurate Intraday Trading Signals - baoquankhu1.vn
Analysts Set XOMA Royalty Corporation (NASDAQ:XOMA) Target Price at $60.60 - Defense World
Short Interest in XOMA Royalty Corporation (NASDAQ:XOMA) Grows By 56.7% - MarketBeat
XOMA Royalty Corporation (NASDAQ:XOMA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Analyzing XOMA Royalty (NASDAQ:XOMA) and Ascendis Pharma A/S (NASDAQ:ASND) - Defense World
Risk Off: What is the next catalyst for XOMA Royalty Corporation2025 Volume Leaders & Short-Term High Return Strategies - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - GlobeNewswire Inc.
Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses - Yahoo Finance
Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty CorporationXOMA - marketscreener.com
XOMA Royalty Corp (NASDAQ: XOMA) appoints new CFO, sets pay terms - stocktitan.net
XOMA Royalty CFO Thomas Burns steps down, Jeffrey Trigilio appointed - Investing.com
XOMA royalty announces CFO transition - MSN
XOMA Royalty Corporation Announces CFO Transition as Thomas Burns Steps Down and Jeffrey Trigilio Takes Over - Quiver Quantitative
Biotech royalty firm XOMA shifts finance leadership after nearly 20 years - Stock Titan
Is XOMA Royalty Corporation stock a defensive play in 20252025 Investor Takeaways & Reliable Price Breakout Signals - Улправда
Will XOMA Royalty Corporation (X0M1) stock profit from fiscal stimulus2026 world cup usa national team quarterfinals top scorers counter attacking tactical prediction breakdown - ulpravda.ru
Implied Volatility Surging for XOMA Royalty Stock Options - Yahoo Finance
XOMA Royalty Corporation (NASDAQ:XOMA) Given Average Rating of “Hold” by Analysts - Defense World
Takeda, XOMA ink new royalty agreement; amend existing deal - MSN
Xoma royalty corp sees sale of $16.98 million in stock by investors - MSN
Antibody Development Company Cleared to Pursue Royalties for Tremfya, Judge Rules - Law.com
Can XOMA Royalty Corporation stock double in next 5 yearsTechnical Analysis Insights & Free Trend Following Techniques - bollywoodhelpline.com
Leerink Partners reiterates Outperform rating on XOMA stock at $45 target - Investing.com India
XOMA and Takeda execute royalty sharing transaction - The Pharma Letter
Takeda regains majority of mezagitamab royalty interest from XOMA - Investing.com
XOMA Royalty: Entitled to Payments Associated - 富途牛牛
Drug royalties reshuffled as XOMA trades part of one for nine experimental drugs - Stock Titan
XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Up 31.7% in December - MarketBeat
XOMA Royalty (XOMAO) Stock Analysis Report | Financials & Insights - Benzinga
XOMA Royalty Declares Quarterly Preferred Stock Dividends - Sahm
XOMA Royalty Corporation Announces Cash Dividends for Preferred Stockholders - Quiver Quantitative
Two XOMA preferred share classes pay cash to holders in January - Stock Titan
Institutional Owners May Consider Drastic Measures as XOMA Royalty Corporation's (NASDAQ:XOMA) Recent US$57m Drop Adds to Long-term Losses - 富途牛牛
XOMA Royalty (NASDAQ:XOMA) shareholders have earned a 13% CAGR over the last three years - Yahoo Finance
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps - MSN
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - RTTNews
Can XOMA Royalty Corporation stock deliver strong Q4 earningsRate Hike & Smart Investment Allocation Insights - Улправда
Generation Bio is latest Mass. biotech to be acquired by Xoma - The Business Journals
Finanzdaten der Xoma Royalty Corp-Aktie (XOMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):